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Background: Despite advances in anti-platelet treatments, there still exists an early increase in both ischemic as
well as bleeding events following primary PCI in patients with ST-elevation myocardial infarction (STEMI). Platelet
inhibition data of different anti-platelet treatments in the acute phase of a myocardial infarction might offer
some insight into these problems. The aim of this study was to evaluate the pharmacodynamic profile of 5 different
anti-platelet treatments in the acute phase of STEMI in patients undergoing primary PCI.
Methods: A total of 223 STEMI patients undergoing primary PCI were prospectively included. Patients received either
pre-hospital clopidogrel only, pre-hospital clopidogrel followed by prasugrel switch in the cath lab, prasugrel treatment
only, pre-hospital clopidogrel followed by ticagrelor switch in the cath lab or pre-hospital ticagrelor only. Platelet
reactivity was measured serially using vasodilator-stimulated phosphoprotein (VASP).
Results: Patients receiving pre-hospital clopidogrel followed by prasugrel switch showed similar platelet inhibition
data as patients receiving prasugrel only, with more than 90% being good responders the day after PCI. Average time
from prasugrel administration to a VASP value of <50% was 1.5 hours. In patients receiving pre-hospital ticagrelor, 50%
were good responders at completion of PCI and average time to a VASP-value of <50% was 2.3 hours. Only 32% of
patients receiving clopidogrel only were responders the day after PCI.
Conclusions: Switching from an upstream bolus dose of clopidogrel to prasugrel at the time of PCI, appeared
as a safe and feasible option with no tendency for overshoot or attenuation of platelet inhibition. Pre-hospital
administration of ticagrelor was associated with a 50% good responder rate at completion of PCI.
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Usage of P2Y12-inhibitors constitutes a cornerstone in the
treatment of acute coronary syndromes, including patients
with ST-elevation myocardial infarction (STEMI) [1-3].
Despite modern P2Y12-inhibitors like prasugrel and
ticagrelor, there still exists an early increase in ischemic
events following primary PCI in patients with STEMI.
Furthermore there is also an immediate increased risk of
bleeding [4]. Although guidelines recommend as early ad-
ministration as possible of P2Y12-inhibitors, clinical data* Correspondence: sasha.koul@med.lu.se
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unless otherwise stated.regarding the timing of P2Y12-inhibitor administration in
STEMI patients is limited [5,6]. Neither prasugrel nor
ticagrelor have any outcome data regarding effects of pre-
treatment in STEMI patients. Clopidogrel pre-treatment
has in register studies and in the small randomized
CIPAMI trial shown promise compared to no pre-treatment
at all, however large randomized data do not exist [7-11].
Platelet inhibition data might give some insight into these
questions, however pharmacodynamic data regarding prasu-
grel, ticagrelor and even clopidogrel in the acute phase of
STEMI is also limited [12,13]. Pre-treatment protocols
with other substances, including GPIIb/IIIa-inhibitors
have been studied with mixed results on various effi-
cacy endpoints [14-16].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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hibition of 5 different anti-platelet protocols in the acute
phase of STEMI in patients undergoing primary PCI.
Methods
Study design
Patients undergoing PCI for STEMI at Skåne University
Hospital in Lund were prospectively included in the Lund
Platelet Registry from October 2009 to October 2012
(total n = 223). All STEMI patients were eligible for in-
clusion. However if the patients had not received a
P2Y12-inhibitor or primary PCI was not performed,
they were excluded. Aspirin treatment was given as
standard treatment unless contraindicated in the indi-
vidual patient. Bivalirudin was used as first-line anti-
thrombotic adjuvant therapy during PCI. Usage of GPIIb/
IIIa-inhibitors were used as bail-out option at the physi-
cian’s discretion (Table 1). Platelet reactivity was measured
serially using a flow cytometric assay for the vasodilator-
stimulated phosphoprotein (VASP) at three time-points:
a) After performed angiography prior to PCI (pre-PCI
VASP) b) after completed PCI procedure (post-PCI VASP)
and c) the following morning after PCI (day after VASP).
A total of 5 different cohorts were included according to





(n = 75) (n = 97)
Age 71 yrs 62 yrs
Male sex 53 (71%) 75 (77%)
Smoking status
Never smoked 29 (39%) 23 (25%)
Previous smoker 28 (37%) 25 (28%)
Current smoker 17 (23%) 43 (47%)
Adjuvant anti- thrombotic
treatment
Aspirin 74 (99%) 91 (94%)
Heparin 72 (96%) 90 (93%)
GpIIb/IIIa-inhibitors 5 (6.7%) 1 (1.1%)
Bivalirudin 70 (93%) 86 (89%)
Prior diseases
Hypertension 46 (61%) 28 (31%)
Myocardial infarction 15 (20%) 7 (7.7%)
Diabetes 6 (8.0%) 11 (12%)
Previous CABG 3 (4.0%) 0 (0%)
Previous PCI 9 (12%) 7 (7.2%)
Insertion of drug eluting
stent
6 (8%) 10 (10%)
GpIIb/IIIa; Glycoprotein IIb/IIIa, CABG; Coronary Arterty Bypass Grafting, PCI; Percutainitiation of the registry all patients were treated with
upstream clopidogrel only (upstream clopidogrel group,
n = 75).
2) As the results of the TRITON trial were published
prasugrel was incorporated into clinical practice as a
bolus dose of prasugrel (60 mg) in the catheterization la-
boratory on top of a previous bolus dose of upstream
clopidogrel (600 mg) in patients with no major risk fac-
tors for bleeding or other contraindications (upstream
clopidogrel-prasugrel switch, n = 97). A weight below 60 kg
or age above 75 years were not considered as contraindi-
cations for a bolus dose prasugrel, however maintenance
therapy for these patients consisted of clopidogrel 75 mg
o.d. A history of stroke or TIA was considered an absolute
contraindication for any use of prasugrel. Prasugrel was
not used in a pre-hospital setting as it was not endorsed in
either national or international guidelines as a pre-hospital
drug at that time. 3) A subset of patients were only given
prasugrel at the cath lab after performed coronary angiog-
raphy (prasugrel cath lab group, n = 11). 4) As ticagrelor
became available, patients were initially given a bolus dose
of clopidogrel upstream (600 mg) followed by a bolus dose
of ticagrelor (180 mg) in the catheterization laboratory
(upstream clopidogrel-ticagrelor switch, n = 10) unless








(n = 11) (n = 10) (n = 30)
61 yrs 64 yrs 65 yrs <0.01
8 (73%) 8 (80%) 20 (67%) 0.74
<0.01
4 (36%) 2 (20%) 5 (17%)
0 (0%) 4 (40%) 6 (20%)
6 (55%) 4 (40%) 16 (53%)
11 (100%) 10 (100%) 30 (100%) 0.09
11 (100%) 10 (100%) 30 (100%) 0.39
1 (9.1%) 0 (0%) 0 (0%) 0.13
11 (100%) 10 (100%) 30 (100%) 0.17
1 (9.1%) 2 (20%) 15 (50%) <0.01
1 (9.1%) 1 (10%) 3 (10%) 0.15
0 (0%) 2 (20%) 5 (17%) 0.42
0 (0%) 0 (0%) 2 (7%) 0.17
0 (0%) 1 (10%) 4 (13%) 0.59
3 (27%) 0 (0%) 7 (23%) 0.06
neous Coronary Intervention.
Figure 1 Clinical protocol. Flow-chart describing the 5 patient cohorts in the study and timings of blood sampling.
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grelor mono-therapy (180 mg) as an upstream bolus dose
(upstream ticagrelor group, n = 30) unless contraindicated.
If patients were deemed not suitable for either prasu-
grel or ticagrelor they were per protocol given clopido-
grel. A recommended treatment duration of at least one
year of P2Y12-inhibition was recommended. Nearly all
patients were given concomitant aspirin (Table 1).
Patient data and clinical follow-up
Patient data was primarily obtained from the Swedish
Coronary Angiography and Angioplasty Registry (SCAAR)
as well as through hospital patient records. The SCAAR
registry includes data from all centres that perform coron-
ary angiography or PCI in Sweden. Based on the unique
Swedish 10-digit personal identification number, the
SCAAR register was merged with other national regis-
tries, including the Swedish Hospital Discharge Registry
and The Register of Information and Knowledge about
Swedish Heart Intensive care Admissions (RIKS-HIA).
VASP-analysis
Platelet reactivity was measured using a commercially avail-
able flow cytometric assay of intraplatelet vasodilator-
stimulated phosphoprotein (VASP), with analyses performedaccording to the manufacturer’s instructions (Biocytex Plate-
let VASP kit, Marseille, FR) [17]. The platelet reactivity index
(VASP-PRI) was calculated from the corrected mean fluores-
cence intensity (cMFI) following incubation of the platelets
with either prostaglandin E1 alone or prostaglandin E1 with
ADP using the formula:
VASP‐PRI% ¼ cMFI PGE1ð Þ−cMFI PGE1þ ADPð Þð Þ=½
cMFI PGE1ð Þ  100%
Endpoints
1. Percentage of patients reaching a VASP PRI-value
of <50% the day after PCI. The cut-off value for
VASP-PRI was selected as a value above 50% has
been associated with worse clinical outcomes following
PCI [18].
2. Average time to reach a VASP PRI-value of <50%.
As safety parameter, major in-hospital bleeding events
were recorded (fatal bleeding/cerebral bleeding/bleeding
requiring surgery or transfusion.
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The study protocol was in accordance with the Declar-
ation of Helsinki. Patient informed consent and ethical
approval was not needed as all blood sampling was part of
routine coronary care and no blood samples were stored
for further usage.Statistical methods
Baseline characteristics were compared across the various
patient groups using ANOVA for continuous parametric
data and Pearson’s chi-squared test for categorical data.
Platelet reactivity as measured by continuous VASP PRI-
values was compared across time-points within treatment
groups using ANOVA for parametric data and Mann-
Whitney’s U-test for non-parametric data. The equality of
variances assumption was tested using Levene’s test. The
proportion of patients reaching a VASP PRI < 50% was
compared using Pearson’s chi-squared test. A p-value <0.05
was considered significant. The risk of major in-hospital
bleeding was evaluated using the Kaplan-Meier estimator,
with censoring at death or loss to follow-up. VASP sam-
pling the day after PCI was performed on fixed times
(between 05.00-06.00) but the time of the day during
which PCI was performed varied (according to when
then the patient arrived to the cath lab). Furthermore
durations of PCI procedures varied, both factors allow-
ing creation of time separation curves. These were cre-
ated using linear regression models with VASP-PRI
regressed on linear or log-transformed time, as appro-
priate from cluster plots. All analyses were performed
using SPSS (SPSS version 18, SPSS Inc, Chicago).Results
Patient characteristics are summarized in Table 1. Upstream
clopidogrel patients were on an average older and had more
comorbidities like hypertension and previous myocardial
infarction than the other groups, in accordance with the
clinical protocol where patients not deemed eligible for
ticagrelor or prasugrel would receive clopidogrel. Anticoa-
gulation with heparin and bivalirudin was often used dur-
ing PCI procedures in the study. Nearly all patients received





Pre-PCI VASP 74% (SD 19) 79% (SD 13)
Post-PCI VASP 74% (SD 20) 74% (SD 21)
Day after PCI VASP 56% (SD 27) 17% (SD 21)
Percentage of patients
with VASP-PRI <50% day
after PCI
32% 90%
VASP; vasodilator-stimulated phosphoprotein, PCI; Percutaneous Coronary InterventClopidogrel upstream group
Patients in the clopidogrel upstream cohort had average
VASP PRI-values of 74% before PCI, 74% after PCI and
56% the day after PCI, as shown in Table 2. The average
VASP-PRI value the day after PCI was significantly lower
than VAS-PRI values pre- and post-PCI (p < 0.001). No
statistically significant difference was noted between VASP
PRI-values pre-PCI and post-PCI (Figure 2). A total of
32% in the clopidogrel upstream group reached a VASP-
PRI value of less than 50% the day after PCI. In the clopi-
dogrel upstream group time-separation curves showed a
weak linear association between time and clopidogrel
response (Figure 3) with a model coefficient of determin-
ation (r2) of 0.17. An average time of 16.7 hours was noted
between clopidogrel administration until a VASP-PRI
value of 50% was reached according to the equation out-
lined in Figure 3. The rate of major in-hospital bleeding
was 4%.
Prasugrel treated patient groups
The average VASP-PRI values for the upstream clopidogrel-
prasugrel switch cohort were 79% before PCI, 74% after PCI
and 17% the day after PCI, as shown in Table 2. A statisti-
cally significant reduction was noted between VASP-PRI
values pre- and post-PCI (p = 0.01) as well as between
VASP PRI-values the day after PCI compared to pre- and
post-PCI (p < 0.001, Figure 2). A total of 90% of patients
reached the pre-specified cutoff value of VASP-PRI <50%
the day after PCI (“good responders”). In time-separation
curves for the upstream clopidogrel-prasugrel switch group
(Figure 4), VASP-PRI appeared to follow an inversely loga-
rithmic association with time, with an r2 of 0.66. Derived
from the equation outlined in Figure 4 the average time
from prasugrel administration to a VASP PRI-value of
50% was 90 minutes. The rate of major in-hospital bleed-
ing was 1.1% in this cohort.
The average VASP-PRI values for the prasugrel cath
lab cohort were 80%, 69% and 19%, as shown in Table 2.
A significant reduction in VASP-PRI values the day after PCI
compared to pre- and post-PCI values was noted (p < 0.01,
Figure 2). A trend towards a reduction in VASP-PRI values
pre- and post-PCI was noted, however not achieving statis-






80% (SD 15) 79% (SD 16) 64% (SD 29)
69% (SD 34) 77% (SD 20) 53% (SD 30)
19% (SD 18) 15% (SD 8) 29% (SD 25)
91% 100% 83%
ion.
Figure 2 Average VASP-PRI values. Box-plot of median and average VASP-PRI values in the various patient cohorts (boxes denote median and
25-75 percentile and whiskers denote 10-90 percentile with outliers. Plus sign in boxes denotes the average value).
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PRI <50% the day after PCI. No patients experienced any
major in-hospital bleedings. Too few values were obtained
in the prasugrel cath lab group to allow a curve fit of
adequate power.
Ticagrelor treated patient groups
The average VASP-PRI values for the upstream ticagrelor
cohort were 64% before PCI, 53% after PCI and 29% the
day after PCI, as shown in Table 2. A statistically significant
reduction was noted between VASP-PRI values pre- and
post-PCI (p = 0.01) as well as between VASP PRI-values the
day after PCI compared to pre- and post-PCI (p < 0.001,
Figure 2). A total of 83% of patients reached the pre-
specified cutoff value of VASP-PRI <50% the day after PCI.
In time-separation curves for the upstream ticagrelor group
(Figure 5), VASP-PRI appeared, just as in upstream
clopidogrel-prasugrel switch patients to follow an in-
versely logarithmic association with time, with an r2 of 0.32.
Derived from the equation outlined in Figure 5 the average
time from ticagrelor administration to a VASP PRI-value of
50% was 2.2 hours in patients receiving upstream ticagrelor.The rate of major in-hospital bleeding was 3.3% in upstream
ticagrelor treated patients.
In upstream clopidogrel-ticagrelor switch patients the
average VASP PRI-values were 79%, 77% and 15% (Table 2).
No difference in VASP-PRI values were noted between
pre- and post-PCI. A significant reduction was noted post-
PCI with all patients in this group being responders the
day after PCI. No major in-hospital bleedings were
noted for these patients. Too few values were obtained
in the upstream clopidogrel-ticagrelor switch group to
allow a curve fit of adequate power.
Comparisons between treatment groups
For VASP PRI-values pre-PCI, patients treated with up-
stream ticagrelor had numerically lower values compared
to all other groups, but the difference was not statistically
significant. Post-PCI the upstream ticagrelor group had
statistically significantly lower VASP-PRI values compared
to all other groups and 50% of upstream ticagrelor pa-
tients had achieved a VASP-PRI value of <50% post-PCI.
However the day after PCI, prasugrel patient groups
showed lower VASP-PRI values compared to upstream
Figure 3 Regression curve upstream clopidogrel. VASP values as function of time in upstream clopidogrel patients with a linear
regression plot.
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tients in the prasugrel or ticagrelor groups were re-
sponders the day after PCI, in comparison to 32% in the
pre-hospital clopidogrel group (p < 0.001).
Discussion
The main findings of our study were:
1. In STEMI patients undergoing primary PCI and
given upstream clopidogrel, a switch to prasugrel in
the cath lab (after coronary angiography) led to
similar rates of platelet inhibition the day after PCI
as prasugrel mono-therapy given in the cath lab.
2. STEMI patients given ticagrelor or prasugrel had a
high degree of platelet inhibition the day after PCI
with rates between 80-100% of patients being good
responders according to the high on treatment
reactivity definition of VASP <50%. However patients
given prasugrel showed a higher degree of platelet
inhibition than patients given ticagrelor mono-therapy.
3. Patients given upstream treatment with a modern
P2Y12-inhibitor (in our study only ticagrelor was
used upstream) had in 50% of cases adequate platelet
inhibition at the time of PCI completion.
4. Time taken from prasugrel administration (on top of
upstream clopidogrel) to an average VASP PRI-value
of <50% was 1.5 hours. Corresponding number for
ticagrelor was 2.2 hours. Clopidogrel mono-therapywas associated with a slow and heterogeneous onset
of action with an average of 16.7 hours from drug
administration to a VASP PRI-value of <50%.
Upstream clopidogrel patients
Our study showed in the upstream clopidogrel group a
markedly slow anti-platelet response, a finding shown in
previous STEMI trials with clopidogrel [19]. A majority
of patients did not achieve a VASP-PRI value of <50%
the day after PCI (Figure 2 and Table 2) and the mean
time to reach 50% VASP-PRI was 16.7 hours. These re-
sults differ from more stable patient populations or in
non-ST-elevation acute coronary syndromes where a
600 mg loading dose of clopidogrel was associated with
a more rapid, albeit slower than prasugrel, anti-platelet
response [20-22]. This probably reflects (as mentioned
previously) the physical stress that STEMI patients are
exposed to [23]. Clopidogrel upstream patients showed
in addition to a general slow-onset of action also signifi-
cant heterogeneity in response with an overall weak lin-
ear response. Subsets of patients showed remarkable
early effect, whereas other patients showed marked little
response over time (Figure 3). These results are in ac-
cordance with our current state of knowledge of clopido-
grel response, where patients due to several factors, both
genetic as well acquired factors like diabetes, exhibit a
high degree of variability in clopidogrel response, associ-
ated with different clinical outcomes [24].
Figure 4 Regression curve upstream clopidogrel-prasugrel cath lab. VASP values as function of time in upstream clopidogrel-prasugrel cath
lab patients with a logarithmic regression plot.
Figure 5 Regression curve upstream ticagrelor. VASP values as function of time in upstream ticagrelor patients with a logarithmic
regression plot.
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Current guidelines suggest a loading dose of a P2Y12-
inhibitor as soon as possible in the setting of STEMI
undergoing primary PCI [5,25]. In the TRITON trial, the
vast majority of patients were included after a coronary
angiogram was performed and no large published data
exist regarding the clinical effects of upstream prasugrel
treatment in STEMI patients [1]. Our study did not in-
clude prasugrel upstream since at the time of prasugrel
introduction in Sweden this was not endorsed by either
international or national guidelines. However our data
indicated approximately 1.5 hours from prasugrel ad-
ministration to a platelet “good responder” status in time
separation curves. In previous studies in stable patients
receiving prasugrel, approximate mean time to a 50%
VASP-PRI value was only 30 min [22]. This constitutes a
considerably faster onset than in our study and is prob-
ably explained by that STEMI patients are under formid-
able body stress, receive platelet inhibitors in supine
position and are treated with opiates, all of which reduce
gastrointestinal motility and uptake [19,23].
Our data further suggested that a treatment regimen
of upstream clopidogrel followed by use of prasugrel
after performed coronary angiogram led to a similar de-
gree of platelet inhibition as if giving only prasugrel in
the cath lab. No tendencies for too powerful anti-platelet
effects or for attenuation of anti-platelet effect (as has
been suggested for cangrelor) were noted compared to
prasugrel mono-therapy [26]. Major in-hospital bleeding
rate for this switch group was low (1.1%). These data
suggest that for patients who are given early clopidogrel,
an additional bolus dose of prasugrel after coronary
angiography is a pharmacodynamically feasible option
making it possible to pre-treat all patients upstream with
a low risk and then individualize treatment in cath lab
dependening on risk-benefit ratio. This is of interest
since in several countries neither prasugrel nor ticagrelor
are available pre-hospitally but clopidogrel in general is.
Furthermore addition of prasugrel in the cath lab led to
improved platelet inhibition during PCI, although in the
majority of patients not reaching a VASP-PRI value of
<50% during PCI.
In a subgroup analysis of the TRITON trial, a signifi-
cant and marked reduction in VASP PRI-value was
noted for prasugrel 1–2 hours post loading dose com-
pared to clopidogrel, results similar to ours. However
the patients were not exclusively STEMI patients and
dual treatment with clopidogrel and prasugrel was not
reported [27]. In the FABOLUS PRO trial, prasugrel
alone (n = 52 for the prasugrel-only group) did not
achieve sufficient levels of platelet inhibition during the
first 2 hours in STEMI patients undergoing primary
PCI. Since no further measurements were made until
6 hours post loading, the exact time point where prasugrelalone rendered sufficient degree of platelet inhibition was
not known. Our results indicate a general faster onset of
prasugrel and the differences could possibly be explained
by usage of different techniques for measurement of plate-
let aggregation (light transmission aggregometry versus
VASP) with different cut-off values for adequate degree of
platelet inhibition [13]. Furthermore the majority of pra-
sugrel patients in our study were pre-treated with clopido-
grel compared to the FABOLUS PRO trial [13]. In a
recent study (n = 27), data indicated that the majority of
prasugrel patients were responders after 2 hours (between
65%-80% of patients depending on the method of meas-
urement). These data are in accordance with our results
[12]. However a second recent study (n = 25) showed
lower levels of responder rate at 2 hours (approximately
45%) [28].
Ticagrelor treated patients
Our study showed that the time from upstream ticagrelor
administration to an average VASP PRI-value of <50% was
2.2 hours. Like prasugrel, this constitutes a significantly
slower response compared to stable patients [29]. A previ-
ous study in STEMI patients (n = 28 for ticagrelor) dem-
onstrated that a majority of ticagrelor patients were
responders after 2 hours (54%-68% depending on the
method of measurement), results close to ours [12]. How-
ever ticagrelor was only given in the catheterization la-
boratory in that study. In another recent study (n = 25),
40% of STEMI patients given ticagrelor (in the emergency
room or in the cath lab) were responders after 2 hours, re-
sults close to ours [28]. Our study showed that if ticagrelor
was given very early upstream (most patients given tica-
grelor in the ambulance or referring hospital) 50% were
good responders at the completion of PCI (which cor-
responded to an average time of 2.2 hours after drug
intake).
Switching from upstream clopidogrel to ticagrelor in
the cath lab led to a lesser degree of platelet inhibition
but well within the margin for “good responder status”
compared to ticagrelor monotherapy. These data suggest,
like in prasugrel treated patients, that switching from a
low risk upstream option of clopidogrel followed by tica-
grelor in cath lab depending on the results of the coronary
angiography and after patient assessment is pharmacody-
namically feasible. No major in-hospital bleeding was
noted in the switch group.
Limitations
As registry study of three drugs with different contrain-
dications and combinations, direct clinical comparisons
were not performed due to the inherent risk of selection
bias. Furthermore our study sample sizes for the prasu-
grel cath lab and the upstream clopidogrel-ticagrelor
switch groups were limited in size. Interpretation of data
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ing was used as a safety end-point, but has to be inter-
preted with caution and due to non-randomized data
with few events no comparisons in bleeding events be-
tween groups were made. Having a group with prasugrel
given upstream would have yielded further information;
however at the time of prasugrel introduction in Sweden,
upstream prasugrel was not endorsed in either inter-
national or national Swedish guidelines since the vast
majority of patients in the TRITON trial were given
prasugrel only after coronary angiography (with high
CABG bleeding rates for the prasugrel arm) [1].
Conclusions
In STEMI patients undergoing primary PCI, a switch to
60 mg prasugrel in the cath lab on top of previous up-
stream clopidogrel 600 mg (n = 97), led to similar rates
of platelet inhibition as prasugrel mono-therapy (n = 11)
with a low in-hospital bleeding rate. Patients treated
with prasugrel or ticagrelor demonstrated potent anti-
platelet effects with 83-100% of patients being good re-
sponders the day after PCI compared to only 32% in
patients receiving only clopidogrel. Upstream treatment
with ticagrelor was associated with 50% of patients being
good responders at the completion of PCI.
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